PTC Therapeutics Inc share price logo

PTC Therapeutics Inc Share Price

NASDAQ: PTCT

Mid Cap

$72.25

+0.55

(+0.77%)

Live

as on

PTC Therapeutics Inc Stock Performance

as on April 18, 2026 at 6:12 am IST

  • Day's Low

    Day's High

    $71.33
    $73.42
    downward going graph

    1.27%

    Downside

    1.62%

    Upside

    downward going graph

  • 52 Week's Low

    52 Week's High

    $35.95
    $87.50
    downward going graph

    50.24%

    Downside

    21.11%

    Upside

    downward going graph

PTC Therapeutics Inc share price movements today

Previous Close
$71.70
Open
$73.35
Volume
876.9K
Day's Low - High
$71.33 - $73.42
52 Week Low - High
$35.95 - $87.50

PTC Therapeutics Inc Historical Returns

1 Month Return
+ 6.3 %
3 Month Return
-1.08 %
1 Year Return
+ 51.3 %
3 Year Return
+ 38.87 %
5 Year Return
+ 47.56 %

PTC Therapeutics Inc Stock Fundamentals & Key Indicators

Check PTC Therapeutics Inc market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$5.9B

EPS (TTM)

-1.97

Dividend Yield

0.00%

Quarterly Earnings Growth YOY

0.00%

PE Ratio (TTM)

8.36

Industry PE ratio

-10.552321428571428

PEG Ratio

0.81

EBITDA

895.3M

Revenue (TTM)

1.7B

Profit Margin

39.44%

Return On Equity TTM

-7740.12%

PTC Therapeutics Inc Stock Valuation

Track how PTC Therapeutics Inc P/E has moved over time to understand its valuation trends.

PTC Therapeutics Inc in the last 5 years

  • Overview

  • Trends

Lowest (-29.19x)

March 31, 2026

Industry (-10.55x)

April 17, 2026

Today (8.36x)

April 17, 2026

Highest (9.55x)

December 31, 2025

LowHigh

Today’s Price to Earnings Ratio: 8.36x

PTC Therapeutics Inc vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of PTC Therapeutics Inc with its industry peers.

Company
Analyst View
Market Cap
5 Years Return %PE RatioProfit Margin %
PTC Therapeutics Inc image
PTC Therapeutics Inc
BUY$5.9B47.56%8.3639.44%
Alnylam Pharmaceuticals Inc image
Alnylam Pharmaceuticals Inc
BUY$42.7B130.51%136.818.45%
Vertex Pharmaceuticals Inc image
Vertex Pharmaceuticals Inc
BUY$110.8B98.57%28.4232.94%
BeiGene, Ltd. image
BeiGene, Ltd.
NA$36.8BNA129.845.37%
Regeneron Pharmaceuticals Inc image
Regeneron Pharmaceuticals Inc
BUY$78.9B48.43%17.9831.41%

Stock Returns calculator for PTC Therapeutics Inc Stock including INR - Dollar returns

The PTC Therapeutics Inc stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Impact: The bonus return you make when the US Dollar rises against the Rupee; calculated on the full amount you walk away with, not just what you invested in.

Investment Value

₹1,00,000

  • 1Y

  • 3Y

  • 5Y

  • 7Y

  • 10Y

PTC Therapeutics Inc investment value today

Current value as on today

₹1,65,197

Returns

₹65,197

(+65.2%)

Returns from PTC Therapeutics Inc Stock

₹52,458 (+52.46%)

Dollar Impact

₹12,739 (+12.74%)

Analyst Recommendation on PTC Therapeutics Inc Stock

Based on 20 analysts

BUY

50.00%

Buy

30.00%

Hold

20.00%

Sell

Based on 20 analysts, 50% of analysts recommend a 'BUY' rating for PTC Therapeutics Inc. Average target price of $87.87

PTC Therapeutics Inc Share Price Target

Get share price movements and forecasts by analysts on PTC Therapeutics Inc.

What analysts predicted

17.78%UPSIDE

Target Price

$87.87

Current Price

$72.25

Analyzed by

20 Analysts

Target

$87.87

PTC Therapeutics Inc target price $87.87, a slight upside of 17.78% compared to current price of $72.25. According to 20 analysts rating.

PTC Therapeutics Inc Stock’s Investor Sentiment and Interest

Search interest for PTC Therapeutics Inc Stock has decreased by -31% in the last 30 days, reflecting a downward trend in search activity.

Time period: to

Change:-31% versus previous 30 day period

PTC Therapeutics Inc Quarterly Profit & Loss

All numbers in Millions USD

Sep 2023
Dec 2023
Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Total Revenue
196
307
210
186
196
213
1,176
178
211
164
Gross Profit
187
200
195
171
185
196
1,163
167
95
148
Operating Income
-118
3
-45
-40
-54
-162
970
-34
3
-81
EBITDA
-73
-32
11
-35
-49
-46
971
-33
20
-70
Interest Expense
28
44
40
43
41
41
34
30
32
55
Depreciation
58
80
55
7
6
6
7
7
11
12
Income Before Tax
-166
-157
-84
-85
-97
-94
929
-71
-23
-139
Income Tax Expense
-33
-1
6
13
8
-28
63
-6
-38
-4
Net Income
-132
-155
-91
-99
-106
-65
866
-64
15
-134
Net Profit Margin
-67.64%
-50.74%
-43.58%
-53.12%
-54.20%
-30.91%
73.68%
-36.25%
7.53%
-81.96%

PTC Therapeutics Inc Annual Profit & Loss

All numbers in Millions USD

Dec 2016
Dec 2017
Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Total Revenue
82
194
264
306
380
538
698
937
806
1,730
Gross Profit
82
189
252
294
361
506
654
872
749
1,658
Operating Income
-132
-64
-115
-241
-431
-374
-447
-439
-302
856
EBITDA
-128
-46
-89
-195
-303
-368
-367
-330
-120
887
Interest Expense
8
12
12
12
56
86
90
129
166
152
Depreciation
-
17
26
32
43
64
128
194
75
38
Income Before Tax
-141
-77
-128
-239
-402
-518
-587
-696
-363
696
Income Tax Expense
0
1
0
11
35
5
-28
-69
0
13
Net Income
-142
-79
-128
-251
-438
-523
-559
-626
-363
682
Net Profit Margin
-171.83%
-40.64%
-48.38%
-81.95%
-115.07%
-97.27%
-80.00%
-66.81%
-45.03%
39.44%

PTC Therapeutics Inc Quarterly Cash Flow

All numbers in Millions USD

Dec 2023
Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Net Income
-155
-91
-99
-106
-65
866
-64
15
-134
Operating Cash Flow
-100
70
-71
-76
-30
870
-58
-66
-34
Investing Cash Flow
-94
-114
-65
-42
267
-184
-422
-289
34
Financing Cash Flow
620
0
246
-17
26
9
3
15
302
Change in Cash
428
-45
103
-128
255
700
-462
-344
312

PTC Therapeutics Inc Annual Cash Flow

All numbers in Millions USD

Dec 2017
Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Net Income
-79
-128
-251
-438
-523
-559
-626
-363
682
Operating Cash Flow
-10
-27
-98
-194
-251
-356
-158
-107
711
Investing Cash Flow
13
-42
-387
-561
219
290
-176
44
-861
Financing Cash Flow
44
131
613
668
20
167
646
255
331
Change in Cash
53
57
126
-79
-19
98
314
185
204

Global Institutional Holdings in PTC Therapeutics Inc

Funds
Holdings
BlackRock Inc
8.61%
Wellington Management Company LLP
4.67%
Nuveen, LLC
1.22%
JPMorgan Chase & Co
1.19%
HHG PLC
4.56%
See all

PTC Therapeutics Inc News & Key Events

  • img

    Today's Timeline - 25 March

    Wed, 06:01 PM

    -

    PTC Therapeutics appoints Jessica Chutter to Board of Directors, enhancing leadership with her extensive biotech investment banking experience.

Insights on PTC Therapeutics Inc

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

  • imgPOSITIVE IMPACT

    Best in 3 Years

    img

    In the last 3 years, PTCT has outperformed top 5 stocks with highest market-cap in its industry

  • imgPOSITIVE IMPACT

    Price Rise

    img

    In the last 1 year, PTCT stock has moved up by 51.3%

  • imgPOSITIVE IMPACT

    Best in 1 Year

    img

    In the last 1 year, PTCT has outperformed top 5 stocks with highest market-cap in its industry

  • imgNEGATIVE IMPACT

    Profit Down

    img

    Netprofit is down for the last 2 quarters, 15.89M → -134.96M (in $), with an average decrease of 949.1% per quarter

  • imgNEGATIVE IMPACT

    Revenue Fall

    img

    Revenue is down for the last 2 quarters, 211.00M → 164.67M (in $), with an average decrease of 22.0% per quarter

About PTC Therapeutics Inc

PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to children and adults living with rare disorders in the United States and internationally. The company provides Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children. Its development pipeline products include Sepiapterin for the treatment of phenylketonuria; PTC518 splicing platform, which is being developed for the treatment of Huntington's disease; and inflammation and ferroptosis platforms, including vatiquinone to treat Friedreich's ataxia. The company distributes its products through third-party distributors. It has collaborations with F. Hoffman-La Roche Ltd., Hoffman-La Roche Inc., the SMA Foundation, National Taiwan University, Akcea Therapeutics, Inc., and Shiratori Pharmaceutical Co., Ltd. The company has license and collaboration agreement with Novartis Pharmaceuticals Corporation to develop PTC518 Huntington's disease program. It markets Upstaza, a gene therapy with the brand name Kebilidi in the United States. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in Warren, New Jersey.
OrganisationPTC Therapeutics Inc
Headquarters500 Warren Corporate Center Drive, Warren, NJ, United States, 07059
IndustryBiotechnology
CEODr. Matthew B. Klein F.A.C.S., M.D., M.S.
E-voting on sharesClick here to vote

Key Management of PTC Therapeutics Inc

Name

Title

Mr. Eric Pauwels

Chief Business Officer

Dr. Lee Scott Golden M.D., Ph.D.

Executive VP & Chief Medical Officer

Ms. Ellen Cavaleri

Head of Investor Relations

Dr. Matthew B. Klein F.A.C.S., M.D., M.S.

CEO & Director

Dr. Allan Steven Jacobson Ph.D.

Co-Founder & Independent Director

Dr. Neil Almstead Ph.D.

Chief Technical Operations Officer

Mr. Mark Elliott Boulding J.D.

Executive VP & Chief Legal Officer

Mr. Pierre Gravier M.S.

Chief Financial Officer

Ms. Christine Utter CPA

Senior VP, Chief Accounting Officer & Head of People Services

Ms. Linda Montella Carter

Senior VP & Chief Information Officer

FAQs

What is PTC Therapeutics Inc share price today?

PTC Therapeutics Inc share price today is $72.25 as on . PTC Therapeutics Inc share today touched a day high of $73.42 and a low of $71.33.

What is the 52 week high and 52 week low for PTC Therapeutics Inc share?

PTC Therapeutics Inc share touched a 52 week high of $87.5 on and a 52 week low of $35.95 on . PTC Therapeutics Inc stock price today i.e. is trending at $72.25,which is 17.43% down from its 52 week high and 100.97% up from its 52 week low.

What is PTC Therapeutics Inc's market capitalisation today?

PTC Therapeutics Inc market capitalisation is $0.01T as on .

How to invest in PTC Therapeutics Inc Stock (PTCT) from India?

  1. Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
  2. Step 2: Search for PTC Therapeutics Inc on INDmoney app. Click on Buy button. You can invest as low as $1.5 in PTC Therapeutics Inc Shares that will get you 0.0208 shares as per PTC Therapeutics Inc share price of $72.25 per share as on April 18, 2026 at 12:42 am IST.

What is the minimum amount required to buy PTC Therapeutics Inc Stock (PTCT) from India?

Indian investors can start investing in PTC Therapeutics Inc (PTCT) shares with as little as ₹92.768 or $1 (as of ) using the INDmoney app.
For example: If you want to invest $10 or ₹927.68 in PTC Therapeutics Inc stock (as per the Rupee-Dollar exchange rate as on ). Based on PTC Therapeutics Inc share’s latest price of $72.25 as on April 18, 2026 at 12:42 am IST, you will get 0.1384 shares of PTC Therapeutics Inc. Learn more about fractional shares .

What are the returns that PTC Therapeutics Inc has given to Indian investors in the last 5 years?

PTC Therapeutics Inc stock has given 47.56% share price returns and 25.08% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?